Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) EBIT Margin (2016 - 2022)

Aptevo Therapeutics (APVO) has disclosed EBIT Margin for 8 consecutive years, with 180.19% as the latest value for Q1 2022.

  • Quarterly EBIT Margin rose 10432.0% to 180.19% in Q1 2022 from the year-ago period, while the trailing twelve-month figure was 919.75% through Dec 2022, down 74565.0% year-over-year, with the annual reading at 919.75% for FY2022, 74565.0% down from the prior year.
  • EBIT Margin hit 180.19% in Q1 2022 for Aptevo Therapeutics, down from 110.23% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 87.88% in Q4 2019 to a low of 1439.11% in Q2 2020.
  • Historically, EBIT Margin has averaged 289.41% across 5 years, with a median of 182.3% in 2018.
  • Biggest five-year swings in EBIT Margin: tumbled -126389bps in 2020 and later surged 125512bps in 2021.
  • Year by year, EBIT Margin stood at 208.22% in 2018, then soared by 58bps to 87.88% in 2019, then crashed by -227bps to 287.36% in 2020, then soared by 62bps to 110.23% in 2021, then plummeted by -63bps to 180.19% in 2022.
  • Business Quant data shows EBIT Margin for APVO at 180.19% in Q1 2022, 110.23% in Q4 2021, and 153.42% in Q3 2021.